Congenpharma CG AKE® Syn-Ake: Exploring a New Approach to Anti-Wrinkle Skincare
Publish Time:
2026-11-11
From Rapid Modulation of Muscle Cell Contraction to Visible Skin Texture Improvements in 28 Days
As consumers increasingly seek effective anti-aging solutions, targeted bioactive peptides are becoming valuable ingredients in the development of advanced skincare formulations.
CG AKE® , developed by Congenpharma, is a biomimetic peptide ingredient designed for advanced anti-wrinkle skincare applications. Through muscle cell contraction studies and 28-day skin efficacy evaluations, CG AKE® demonstrates promising potential in supporting wrinkle care, skin smoothness, and the development of innovative anti-aging formulations.
1. Rapid Action: Significant Reduction in Muscle Cell Contraction Frequency
Under the tested condition of 0.5 mM CG AKE®, experimental results demonstrated a notable reduction in muscle cell contraction frequency.
Compared with baseline measurements, the following results were observed:
After 1 minute: 36% reduction in muscle cell contraction frequency.
After 2 hours: 82% reduction, representing the most pronounced observed effect.
After 2T: 67% reduction.
After 4T: Contraction frequency gradually returned toward the baseline level.
These findings indicate that CG AKE® can effectively modulate muscle cell contraction frequency under specific experimental conditions, highlighting its potential for applications targeting expression-line care.
2. 28-Day Efficacy Evaluation: Improving Wrinkles and Skin Texture
In addition to cellular studies, Congenpharma conducted a 28-day skin efficacy evaluation to further investigate the performance of CG AKE® in anti-wrinkle skincare applications.
A. Improved Forehead Wrinkles and Skin Smoothness
After 28 days, the tested CG AKE® formulation demonstrated improvements in several skin surface and wrinkle-related parameters compared with the control group:
Ra (Average Roughness): Approximately 21% improvement.
Rz (Skin Profile Depth): Approximately 20% improvement.
Rt (Total Profile Height): Approximately 15% improvement.
The original test data indicate statistical significance for certain parameters (*p < 0.05; **p = 0.01).
These results suggest that CG AKE® has promising potential in improving skin surface roughness and wrinkle-related characteristics.
B. Improved Crow's Feet Appearance and Skin Texture
Skin texture imaging taken before and after 28 days of treatment revealed positive changes in the tested skin areas.
The comparison between Day 0 and Day 28 provides additional visual evidence supporting the potential of CG AKE® in improving wrinkle depth and skin surface texture.
3. Biomimetic Peptide Technology for Next-Generation Anti-Wrinkle Formulations
By combining muscle cell contraction studies with 28-day skin efficacy evaluations, CG AKE® offers a multi-dimensional approach to exploring peptide-based anti-wrinkle applications.
For cosmetic brands seeking to develop innovative products targeting wrinkles, fine lines, and skin smoothness, CG AKE® provides an interesting active ingredient option for differentiated skincare formulations.
4. Congenpharma: Driving Cosmetic Ingredient Innovation Through Science
Congenpharma is committed to the development and application of innovative cosmetic ingredients, with a focus on bioactive peptides and functional skincare ingredients.
By integrating scientific research with evolving market needs, Congenpharma strives to provide professional ingredient solutions to cosmetic brands worldwide.
From cellular research to skin efficacy evaluation, Congenpharma continues to explore the potential of innovative active ingredients to support the development of advanced skincare products.
CG AKE® — Biomimetic Peptide Technology for the Next Generation of Anti-Wrinkle Skincare.
Frequently Asked Questions (FAQ)
Q1: What is CG AKE® ?
CG AKE® is a biomimetic snake venom-inspired peptide ingredient developed by Congenpharma for cosmetic anti-wrinkle and advanced skincare formulations.
Q2: What are the key benefits of CG AKE®?
CG AKE® has demonstrated muscle cell contraction modulation in an in-vitro study and improvements in skin surface parameters in a 28-day skin evaluation. It offers potential for anti-wrinkle and skin texture care applications.
Q3: What is the reported muscle cell contraction reduction of CG AKE®?
Under the reported in-vitro test condition of 0.5 mM, CG AKE® demonstrated an 82% reduction in muscle cell contraction frequency after 2 hours.
Q4: What skin parameters were evaluated in the 28-day study?
The supplied test data include Ra (average roughness), Rz (skin profile depth), and Rt (total profile height), with reported improvements of approximately 21%, 20%, and 15%, respectively.
Q5: What cosmetic products can incorporate CG AKE®?
Potential applications include anti-wrinkle serums, eye creams, firming creams, and advanced anti-aging skincare formulations. Actual suitability depends on formulation compatibility and finished-product testing.
Q6: Does the reported 82% reduction mean an 82% reduction in human wrinkles?
No. The 82% result refers specifically to muscle cell contraction frequency in an in-vitro experiment. It should not be interpreted as an equivalent percentage of wrinkle reduction in human skin.
Q7: Where can I obtain more information about CG AKE®?
For technical specifications, formulation guidance, and product inquiries, please contact Congenpharma through www.congenpharm.com.
CONGENPHARMA
Innovative Ingredients. Advanced Skincare.
Your Trust Cosmetic Active Ingredients Partner-CongenPharma
Prev:
Relevant Information
undefined
